Protease inhibitor SERPINA1 expression in epithelial ovarian cancer

Clinical and Experimental Metastasis

Volumn 27, Issue 1, 2010, Pages 55-69

  Normandin, Karine ^a   Péant, Benjamin ^a   Le Page, Cécile ^a   De Ladurantaye, Manon ^a   Ouellet, Véronique ^a   Tonin, Patricia N ^c   Provencher, Diane M ^a,b   Mes Masson, Anne Marie ^d  

^a Institut du Cancer de Montreal   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Biological effects; Epithelial ovarian cancer; Ovarian cell lines; Protease inhibitor; SERPINA1

Indexed keywords

COMPLEMENTARY DNA; ENZYME INHIBITOR; SERPIN PEPTIDASE INHIBITOR CLADE A 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CELL ASSAY; CELL MIGRATION; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; EPITHELIAL OVARY CANCER; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MOLECULAR CLONING; MOUSE; NONHUMAN; OVARY CANCER; PLASMID; POLYMERASE CHAIN REACTION; PROTEIN LOCALIZATION; SEVERE COMBINED IMMUNODEFICIENCY; TISSUE MICROARRAY; TUMOR GROWTH; TUMOR PROMOTION;

ALPHA 1-ANTITRYPSIN; ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, SCID; OVARIAN NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 74849111706     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-009-9303-6     Document Type: Article

References (64)

1. J Permuth-Wey TA Sellers 2009 Epidemiology of ovarian cancer Methods Mol Biol 472 413 437 10.1007/978-1-60327-492-0-20 19107446
2. N Colombo T Van Gorp G Parma, et al. 2006 Ovarian cancer Crit Rev Oncol Hematol 60 159 179 10.1016/j.critrevonc.2006.03.004 17018256 (Pubitemid 44636248)
3. DA Bell 2005 Origins and molecular pathology of ovarian cancer Mod Pathol 18 Suppl 2 S19 S32 10.1038/modpathol.3800306 15761464 (Pubitemid 40188615)
4. CP Crum R Drapkin D Kindelberger, et al. 2007 Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer Clin Med Res 5 35 44 10.3121/cmr.2007.702 17456833 (Pubitemid 350218778)
5. CP Crum R Drapkin A Miron, et al. 2007 The distal fallopian tube: a new model for pelvic serous carcinogenesis Curr Opin Obstet Gynecol 19 3 9 10.1097/GCO.0b013e328011a21f 17218844 (Pubitemid 46095865)
6. Benedet JL (2006) Staging classifications and clinical practice guidelines for gynaecologic cancers. In: Publications of the international federation of gynecology and obstetrics. Available via http://www.figo.org/ publications
7. DA Bell TA Longacre J Prat, et al. 2004 Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives Hum Pathol 35 934 948 10.1016/j.humpath.2004.03.005 15297961 (Pubitemid 39037177)
8. G Singer R Oldt III Y Cohen, et al. 2003 Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J Natl Cancer Inst 95 484 486 12644542
9. G Singer R Stohr L Cope, et al. 2005 Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation Am J Surg Pathol 29 218 224 10.1097/01.pas. 0000146025.91953.8d 15644779 (Pubitemid 40170640)
10. T Bonome JY Lee DC Park, et al. 2005 Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary Cancer Res 65 10602 10612 10.1158/0008-5472.CAN-05-2240 16288054 (Pubitemid 41743756)
11. VW Chen B Ruiz JL Killeen, et al. 2003 Pathology and classification of ovarian tumors Cancer 97 2631 2642 10.1002/cncr.11345 12733128
12. AF Chambers AC Groom IC MacDonald 2002 Dissemination and growth of cancer cells in metastatic sites Nat Rev Cancer 2 563 572 10.1038/nrc865 12154349 (Pubitemid 37328923)
13. P Friedl K Wolf 2003 Tumour-cell invasion and migration: diversity and escape mechanisms Nat Rev Cancer 3 362 374 10.1038/nrc1075 12724734 (Pubitemid 37328856)
14. S Aznavoorian AN Murphy WG Stetler-Stevenson, et al. 1993 Molecular aspects of tumor cell invasion and metastasis Cancer 71 1368 1383 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L 8435813 (Pubitemid 23054933)
15. MJ Duffy 1992 The role of proteolytic enzymes in cancer invasion and metastasis Clin Exp Metastasis 10 145 155 10.1007/BF00132746 1582084
16. MJ Duffy 1996 Proteases as prognostic markers in cancer Clin Cancer Res 2 613 618 9816210
17. M Schmitt 1992 Tumor associated proteases Fibrinolysis 6 3 26 10.1016/0268-9499(92)90003-Z
18. PG Gettins 2002 Serpin structure, mechanism, and function Chem Rev 102 4751 4804 10.1021/cr010170+ 12475206
19. D van Gent P Sharp K Morgan, et al. 2003 Serpins: structure, function and molecular evolution Int J Biochem Cell Biol 35 1536 1547 10.1016/S1357-2725(03) 00134-1 12824063 (Pubitemid 36724947)
20. PJ de Koning N Bovenschen FK Leusink, et al. 2009 Downregulation of SERPINB13 expression in head and neck squamous cell carcinomas associates with poor clinical outcome Int J Cancer 125 1542 1550 10.1002/ijc.24507 19569240
21. DR Croucher DN Saunders S Lobov, et al. 2008 Revisiting the biological roles of PAI2 (SERPINB2) in cancer Nat Rev Cancer 8 535 545 10.1038/nrc2400 18548086 (Pubitemid 351881848)
22. CM Bailey Z Khalkhali-Ellis EA Seftor, et al. 2006 Biological functions of maspin J Cell Physiol 209 617 624 10.1002/jcp.20782 17001697 (Pubitemid 44665678)
23. Z Zou A Anisowicz MJ Hendrix, et al. 1994 Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells Science 263 526 529 10.1126/science.8290962 8290962
24. NL Sieben J Oosting AM Flanagan, et al. 2005 Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors J Clin Oncol 23 7257 7264 10.1200/JCO.2005.02.2541 16087957 (Pubitemid 46202340)
25. K Tamura M Furihata T Tsunoda, et al. 2007 Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles Cancer Res 67 5117 5125 10.1158/0008-5472.CAN-06-4040 17545589 (Pubitemid 46997247)
26. S Warrenfeltz S Pavlik S Datta, et al. 2004 Gene expression profiling of epithelial ovarian tumours correlated with malignant potential Mol Cancer 3 27 10.1186/1476-4598-3-27 15471544 (Pubitemid 40230545)
27. JA Carlson BB Rogers RN Sifers, et al. 1988 Multiple tissues express alpha 1-antitrypsin in transgenic mice and man J Clin Invest 82 26 36 10.1172/JCI113580 3260605
28. RW Carrell 1986 alpha 1-Antitrypsin: molecular pathology, leukocytes, and tissue damage J Clin Invest 78 1427 1431 10.1172/JCI112731 3537008
29. N Kalsheker S Morley K Morgan 2002 Gene regulation of the serine proteinase inhibitors alpha1-antitrypsin and alpha1-antichymotrypsin Biochem Soc Trans 30 93 98 10.1042/BST0300093 12023832
30. T Kohnlein T Welte 2008 Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment Am J Med 121 3 9 10.1016/j.amjmed.2007.07.025 18187064
31. RH Law Q Zhang S McGowan, et al. 2006 An overview of the serpin superfamily Genome Biol 7 216 10.1186/gb-2006-7-5-216 16737556 (Pubitemid 44782985)
32. B Lisowska-Myjak 2005 AAT as a diagnostic tool Clin Chim Acta 352 1 13 10.1016/j.cccn.2004.03.012 15653097 (Pubitemid 40093854)
33. GA Silverman PI Bird RW Carrell, et al. 2001 The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature J Biol Chem 276 33293 33296 10.1074/jbc.R100016200 11435447
34. J Travis GS Salvesen 1983 Human plasma proteinase inhibitors Annu Rev Biochem 52 655 709 10.1146/annurev.bi.52.070183.003255 6193754
35. V Ouellet M Zietarska L Portelance, et al. 2008 Characterization of three new serous epithelial ovarian cancer cell lines BMC Cancer 8 152 10.1186/1471-2407-8-152 18507860 (Pubitemid 352044775)
36. DM Provencher H Lounis L Champoux, et al. 2000 Characterization of four novel epithelial ovarian cancer cell lines In Vitro Cell Dev Biol Anim 36 357 361 10.1290/1071-2690(2000)036<0357:COFNEO>2.0.CO;2 10949993
37. V Ouellet DM Provencher CM Maugard, et al. 2005 Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling Oncogene 24 4672 4687 10.1038/sj.onc.1208214 15940270 (Pubitemid 41032604)
38. ML Puiffe C Le Page A Filali-Mouhim, et al. 2007 Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer Neoplasia 9 820 829 10.1593/neo.07472 17971902 (Pubitemid 47623422)
39. JP Novak R Sladek TJ Hudson 2002 Characterization of variability in large-scale gene expression data: implications for study design Genomics 79 104 113 10.1006/geno.2001.6675 11827463
40. TR Golub DK Slonim P Tamayo, et al. 1999 Molecular classification of cancer: class discovery and class prediction by gene expression monitoring Science 286 531 537 10.1126/science.286.5439.531 10521349
41. VG Tusher R Tibshirani G Chu 2001 Significance analysis of microarrays applied to the ionizing radiation response Proc Natl Acad Sci U S A 98 5116 5121 10.1073/pnas.091062498 11309499 (Pubitemid 32397092)
42. B Peant JS Diallo F Dufour, et al. 2009 Over-expression of IkappaB-kinase-epsilon (IKKepsilon/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines Prostate 69 706 718 10.1002/pros.20912 19170126
43. K Wolf YI Wu Y Liu, et al. 2007 Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion Nat Cell Biol 9 893 904 10.1038/ncb1616 17618273 (Pubitemid 47190444)
44. D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 57 70 10.1016/S0092-8674(00)81683-9 10647931
45. T Ludwig 2005 Local proteolytic activity in tumor cell invasion and metastasis Bioessays 27 1181 1191 10.1002/bies.20306 16237672 (Pubitemid 43076144)
46. T Sato S Takahashi T Mizumoto, et al. 2006 Neutrophil elastase and cancer Surg Oncol 15 217 222 10.1016/j.suronc.2007.01.003 17320378 (Pubitemid 46771195)
47. M Kobel SE Kalloger N Boyd, et al. 2008 Ovarian carcinoma subtypes are different diseases: implications for biomarker studies PLoS Med 5 e232 10.1371/journal.pmed.0050232 19053170
48. W Li AY Savinov DV Rozanov, et al. 2004 Matrix metalloproteinase-26 is associated with estrogen-dependent malignancies and targets alpha1-antitrypsin serpin Cancer Res 64 8657 8665 10.1158/0008-5472.CAN-04-3019 15574774 (Pubitemid 39552080)
49. CJ O'Neill HA McBride LE Connolly, et al. 2007 High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour Histopathology 50 773 779 10.1111/j.1365-2559.2007.02682.x 17493241 (Pubitemid 46683935)
50. V Ouellet TH Ling K Normandin, et al. 2008 Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors BMC Cancer 8 346 10.1186/1471-2407-8-346 19032793
51. KM Schmeler DM Gershenson 2008 Low-grade serous ovarian cancer: a unique disease Curr Oncol Rep 10 519 523 10.1007/s11912-008-0078-8 18928667
52. K Wolf I Mazo H Leung, et al. 2003 Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis J Cell Biol 160 267 277 10.1083/jcb.200209006 12527751 (Pubitemid 36254960)
53. SY Wong RO Hynes 2006 Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide? Cell Cycle 5 812 817 16627996
54. R Taetle M Aickin JM Yang, et al. 1999 Chromosome abnormalities in ovarian adenocarcinoma: I. Nonrandom chromosome abnormalities from 244 cases Genes Chromosomes Cancer 25 290 300 10.1002/(SICI)1098-2264(199907)25:3<290:: AID-GCC12>3.0.CO;2-G 10379876 (Pubitemid 29266699)
55. A Bagdasarian J Wheeler GJ Stewart, et al. 1981 Isolation of alpha 1-protease inhibitor from human normal and malignant ovarian tissue J Clin Invest 67 281 291 10.1172/JCI110025 6161137
56. T Ny P Wahlberg IJ Brandstrom 2002 Matrix remodeling in the ovary: regulation and functional role of the plasminogen activator and matrix metalloproteinase systems Mol Cell Endocrinol 187 29 38 10.1016/S0303-7207(01) 00711-0 11988309 (Pubitemid 34441038)
57. H Allgayer R Babic KU Grutzner, et al. 1998 Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns Clin Exp Metastasis 16 62 73 10.1023/A:1006564002679 9502078 (Pubitemid 28122556)
58. S Karashima H Kataoka H Itoh, et al. 1990 Prognostic significance of alpha-1-antitrypsin in early stage of colorectal carcinomas Int J Cancer 45 244 250 10.1002/ijc.2910450207 2303291
59. M Higashiyama O Doi K Kodama, et al. 1992 An evaluation of the prognostic significance of alpha-1-antitrypsin expression in adenocarcinomas of the lung: an immunohistochemical analysis Br J Cancer 65 300 302 1739634
60. JN Kloth A Gorter GJ Fleuren, et al. 2008 Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma J Pathol 215 222 230 10.1002/path.2347 18438953 (Pubitemid 351956703)
61. AK Sood MS Fletcher LM Gruman, et al. 2002 The paradoxical expression of maspin in ovarian carcinoma Clin Cancer Res 8 2924 2932 12231537
62. D Keppler M Markert B Carnal, et al. 1996 Human colon carcinoma cells synthesize and secrete alpha 1-proteinase inhibitor Biol Chem Hoppe Seyler 377 301 311 8828821
63. J Yavelow A Tuccillo SS Kadner, et al. 1997 Alpha 1-antitrypsin blocks the release of transforming growth factor-alpha from MCF-7 human breast cancer cells J Clin Endocrinol Metab 82 745 752 10.1210/jc.82.3.745 9062476 (Pubitemid 27106581)
64. TT Lah MB Duran Alonso CJ Van Noorden 2006 Antiprotease therapy in cancer: hot or not? Expert Opin Biol Ther 6 257 279 10.1517/14712598.6.3.257 16503735 (Pubitemid 43344745)